Pharm Exec18h
Treating Disruptive Symptom’s in Crohn’s Patients: Q&A with Mark Genovese, MD
Mark Genovese: Crohn’s disease is a chronic, inflammatory bowel disease associated with progressive bowel damage, disability, ...
GlobalData on MSN16h
Novo Nordisk secures FDA approval for Ozempic in diabetes with CKD
The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks ...
GlobalData on MSN20h
FDA RMAT designation for Beacon’s retinitis pigmentosa treatment
The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to Beacon ...
PMLiVE17h
Biogen’s higher dose spinal muscular atrophy regimen accepted for review by EMA/FDA
Biogen has announced that the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) have started ...
AstraZeneca's SWOT analysis: pharma giant's stock poised for growth amid challenges
AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...
US FDA approves Novo Nordisk's Ozempic to reduce risk of kidney diseases in diabetic patients
Breakthrough in diabetes treatment! The US FDA approves Ozempic for reducing kidney disease risk in diabetic patients. Learn ...
Hosted on MSN13h
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study
Shares of Akero Therapeutics AKRO skyrocketed 105.7% in a week after the company announced initial positive top line 96-week ...